D&A
Agilent Technologies D&A decreased by 5.6% to $67.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.9%, from $72.00M to $67.00M. Over 4 years (FY 2021 to FY 2025), D&A shows a downward trend with a -2.7% CAGR.
Analysis
How to read this metric
Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
Detailed definition
This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...
Peer comparison
Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.
depreciation_and_amortization_cfHistorical Data
| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $77.00M | $84.00M | $84.00M | $82.00M | $82.00M | $80.00M | $73.00M | $67.00M | $71.00M | $71.00M | $62.00M | $62.00M | $63.00M | $63.00M | $69.00M | $72.00M | $73.00M | $72.00M | $71.00M | $67.00M |
| QoQ Change | — | +9.1% | +0.0% | -2.4% | +0.0% | -2.4% | -8.8% | -8.2% | +6.0% | +0.0% | -12.7% | +0.0% | +1.6% | +0.0% | +9.5% | +4.3% | +1.4% | -1.4% | -1.4% | -5.6% |
| YoY Change | — | — | — | — | +6.5% | -4.8% | -13.1% | -18.3% | -13.4% | -11.3% | -15.1% | -7.5% | -11.3% | -11.3% | +11.3% | +16.1% | +15.9% | +14.3% | +2.9% | -6.9% |
Business Segments
| Segment | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 |
|---|---|---|---|---|---|---|---|---|
| Life Sciences and Diagnostics Markets | $15.00M | $15.00M | — | $18.00M | $18.00M | $18.00M | $18.00M | $23.00M |
| Agilent CrossLab | $6.25M | $6.25M | $6.25M | $7.25M | $7.25M | $7.25M | $7.25M | $14.00M |
| Applied Markets | $5.50M | $5.50M | — | $5.75M | $5.75M | $5.75M | $5.75M | $6.00M |
| Diagnostics and Genomics | $10.00M | $10.00M | $10.00M | $14.00M | $14.00M | $14.00M | — | — |
| Life Sciences and Applied Markets | $15.75M | $15.75M | $15.75M | $16.00M | $16.00M | $16.00M | — | — |
| Total | $71.00M | $71.00M | $62.00M | $62.00M | $63.00M | $63.00M | $69.00M | $72.00M |
Diagnostics and Genomics, Life Sciences and Applied Markets are derived from annual filings.
Agilent CrossLab, Applied Markets, Diagnostics and Genomics, Life Sciences and Applied Markets, Life Sciences and Diagnostics Markets were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
D&A at Other Companies
Frequently Asked Questions
- What is Agilent Technologies's d&a?
- Agilent Technologies (A) reported d&a of $67.00M in Q4 2025.
- How has Agilent Technologies's d&a changed year-over-year?
- Agilent Technologies's d&a decreased by 6.9% year-over-year, from $72.00M to $67.00M.
- What is the long-term trend for Agilent Technologies's d&a?
- Over 4 years (2021 to 2025), Agilent Technologies's d&a has grown at a -2.7% compound annual growth rate (CAGR), from $321.00M to $288.00M.
- What does d&a mean?
- The accounting process of spreading the cost of physical and intangible assets over time.